Prescription Justice heartily endorses Utah bill HB 163, The Prescription Drug Affordability Act, and applauds Utah Representative Norman Thurston (R-63), its lead sponsor. The bill envisions the federal government permitting Utah to import wholesale quantities of FDA-approved drugs from Canada, which would then be dispensed to patients at retail pharmacies and hospitals in Utah. Canadian wholesale pharmacy prices are much lower on many expensive brand name drugs. Utahans would stand to save hundreds of millions of dollars on their collective pharmacy bill.
Prescription Justice recently joined with nine other health, social justice and consumer advocacy organizations to launch a petition to demand Congress act to bring relief to the millions of Americans who can't afford the prescription drugs they need. The online petition largely echoes the Prescription Justice policy platform which prioritizes ending the ban on Medicare negotiating drug prices, making pay-for-delay deals illegal, and permitting wider access to lower-cost, imported medication through legislative, regulatory, and policy reforms.
As we leave 2017 behind, the crisis of high prescription drug prices continues to threaten the health and well-being of Americans who struggle to access life-saving medications. Millions of Americans are forced to choose between taking the medicine they need, paying the rent or buying food for their families; tens of millions don’t take prescribed medication; and federal and state budgets are overwhelmed. At Prescription Justice, we are dedicated solely to putting an end to this devastating crisis.
Last week, Gabriel Levitt, founder of Prescription Justice, published an Op-Ed in The Guardian about Alex Azar, President Trump’s nominee for Secretary of the Department of Health and Human Services (HHS). Mr. Levitt’s Op-Ed, Alex Azar is big pharma personified. He must not become US health secretary, underscores the urgent need for members of Congress to oppose Azar’s confirmation.
President Trump reinvigorated the drug price policy debate by recently stating that prescription drug prices "are out of control" and, for a second time, that drug companies are "getting away with murder." He's expected to soon announce a bi-partisan drug price task force to examine prescription drug costs. The president's renewed focus on lowering drug costs is a relief from the misaligned priority of healthcare reform, which seems to have overshadowed Americans most pressing healthcare concern: soaring drug costs.